Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Inclusion Criteria:

• Signed informed consent
• Non-smokers
• Type II DM diagnosed patients
• Blood pressure < 135/90
• Serum HbA1C > 7%
• Serum creatinine < 1mg%
• Urine microalbumin < 300 mg/day
• Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

• Insulin-dependent diabetic patients
• Patient with persistent microalbuminuria
• Patient with history of severe hypertension
• Congestive heart failure
• Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
• Patient with major hepatic disease